{"id":9623,"date":"2026-11-06T08:00:00","date_gmt":"2026-11-06T06:00:00","guid":{"rendered":"https:\/\/www.msd.ch\/fr\/?post_type=news_item&#038;p=9623"},"modified":"2026-11-05T17:09:32","modified_gmt":"2026-11-05T15:09:32","slug":"autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle","status":"publish","type":"news_item","link":"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/","title":{"rendered":"Swissmedic autorise KEYTRUDA\u00ae (pembrolizumab) en association avec l\u2019enfortumab vedotin (EV) comme traitement avant et apr\u00e8s une intervention chirurgicale chez les adultes atteints d\u2019un cancer de la vessie infiltrant le muscle (MIBC)."},"content":{"rendered":"","protected":true},"excerpt":{"rendered":"","protected":true},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"footnotes":""},"tags":[30],"class_list":["post-9623","news_item","type-news_item","status-publish","post-password-required","hentry","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Autorisation de KEYTRUDA\u00ae pour le cancer de la vessie | MSD<\/title>\n<meta name=\"description\" content=\"Swissmedic autorise KEYTRUDA\u00ae en association avec l\u2019enfortumab vedotin pour le traitement p\u00e9riop\u00e9ratoire du cancer de la vessie infiltrant le muscle.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Autorisation de KEYTRUDA\u00ae pour le cancer de la vessie | MSD\" \/>\n<meta property=\"og:description\" content=\"Swissmedic autorise KEYTRUDA\u00ae en association avec l\u2019enfortumab vedotin pour le traitement p\u00e9riop\u00e9ratoire du cancer de la vessie infiltrant le muscle.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/\" \/>\n<meta property=\"og:site_name\" content=\"msd.ch\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"10 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\\\/\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\\\/\",\"name\":\"Autorisation de KEYTRUDA\u00ae pour le cancer de la vessie | MSD\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/#website\"},\"datePublished\":\"2026-11-06T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/news\\\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\\\/#breadcrumb\"},\"inLanguage\":\"en-US\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/\",\"name\":\"msd.ch\",\"description\":\"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.msd.ch\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Autorisation de KEYTRUDA\u00ae pour le cancer de la vessie | MSD","description":"Swissmedic autorise KEYTRUDA\u00ae en association avec l\u2019enfortumab vedotin pour le traitement p\u00e9riop\u00e9ratoire du cancer de la vessie infiltrant le muscle.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/","og_locale":"en_US","og_type":"article","og_title":"Autorisation de KEYTRUDA\u00ae pour le cancer de la vessie | MSD","og_description":"Swissmedic autorise KEYTRUDA\u00ae en association avec l\u2019enfortumab vedotin pour le traitement p\u00e9riop\u00e9ratoire du cancer de la vessie infiltrant le muscle.","og_url":"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/","og_site_name":"msd.ch","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"10 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/","url":"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/","name":"Autorisation de KEYTRUDA\u00ae pour le cancer de la vessie | MSD","isPartOf":{"@id":"https:\/\/www.msd.ch\/fr\/#website"},"datePublished":"2026-11-06T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/www.msd.ch\/fr\/news\/autorisation-de-keytruda-en-association-avec-enfortumab-vedotin-comme-traitement-perioperatoire-chez-les-adultes-atteints-dun-cancer-de-la-vessie-infiltrant-le-muscle\/#breadcrumb"},"inLanguage":"en-US"},{"@type":"WebSite","@id":"https:\/\/www.msd.ch\/fr\/#website","url":"https:\/\/www.msd.ch\/fr\/","name":"msd.ch","description":"MSD recherche et d\u00e9veloppe des m\u00e9dicaments et des vaccins pour sauver des vies et am\u00e9liorer la sant\u00e9 des patients. En Suisse, 1000 employ\u00e9s \u00e0 Lucerne et \u00e0 Zurich s&#039;engagent dans ce sens.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.msd.ch\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/9623","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":10,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/9623\/revisions"}],"predecessor-version":[{"id":9654,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/news_item\/9623\/revisions\/9654"}],"wp:attachment":[{"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/media?parent=9623"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.msd.ch\/fr\/wp-json\/wp\/v2\/tags?post=9623"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}